Muna Alnimri, M.B.B.S.

Philosophy of Care	Dr. Alnimri is interested in desensitization protocols and new trials in immunosuppression.
Clinical Interests	Dr. Alnimri's goal is to provide outstanding medical care to patients, to participate in teaching residents and medical students and to be involved in clinical research and new trials of immunosuppressive medications.
Title	Associate Professor
Specialty	Internal Medicine, Nephrology, Surgery - Transplant
Department	Internal Medicine
Division	Transplant Nephrology
Clinic	Transplant
Center/Program Affiliation	Transplant Center
Address/Phone	UC Davis Medical Center, Cypress Building, Transplant Surgery, 2221 Stockton Blvd. Suite B Sacramento, CA 95817 **Phone:** 916-734-2111
Additional Phone	Physician Referrals: 800-4-UCDAVIS (800-482-3284)
Languages	Arabic
Education	M.B.B.S., Jordan University School of Medicine, Jordan, 1987
Internships	Jordan University School of Medicine, Jordan 1987-1988
Residency	Kent and Canterbury Hospital, 1993-1994 King Hussein Medical Center, 1988-1993 Unity Health System, Rochester NY 2006-2008
Fellowships	Oregon Health Sciences University, OR 1997-1999 Royal Medical Services, 1988-1993 University of California, San Francisco CA 2008-2009
Board Certifications	American Board of Internal Medicine, 2008 American Board of Nephrology, 2009

UCDAVIS HEALTH

Muna Alnimri, M.B.B.S.

Professional Memberships

American Medical Association
American Society of Nephrology
American Society of Transplantation
International Society of Nephrology
Royal College of Physicians (UK)

Honors and Awards

Fellow of the Royal College of Physicians UK, 2005
Honorary Registrar University College, London, 2001

Select Recent Publications

Alnimri M, Laftavi MR, Kohli R, Said M, Feng L, Patel S, Pankewycz O. African-American women and older patients are at risk for a greater decline in renal function following living kidney donation. Transplant Proc. 2011 Mar;43(2):512-5.

Laftavi MR, Alnimri M, Weber-Shrikant E, Kohli R, Said M, Patel S, Pankewycz O. Low-dose rabbit antithymocyte globulin versus basiliximab induction therapy in low-risk renal transplant recipients: 8-year follow-up. Transplant Proc. 2011 Mar;43(2):458-61.

Laftavi MR, Hai F, Laftavi H, Feng L, Said M, Patel S, Kohli R, Alnimri M, Dayton M, Pankewycz O. Mycophenolic acid dose reductions result in poor long-term renal allograft survival: comparison between mycophenolate sodium and mycophenolate mofetil. Transplant Proc. 2011 Mar;43(2): 478-81.

Laftavi MR, Patel S, Soliman MR, Alnimri M, Kohli R, Said M, Pankewycz O. Low-dose thymoglobulin use in elderly renal transplant recipients is safe and effective induction therapy. Transplant Proc. 2011 Mar;43(2):466-8.

Pankewycz O, Leca N, Kohli R, Wallace PK, Said M, Feng L, Alnimri M, Patel S, Laftavi MR. Low-dose rabbit antithymocyte globulin induction therapy results in prolonged selective lymphocyte depletion irrespective of maintenance immunosuppression. Transplant Proc. 2011 Mar;43(2):462-5.

Pankewycz O, Leca N, Kohli R, Weber-Shrikant E, Said M, Alnimri M, Feng L, Patel S, Laftavi MR. Conversion to low-dose tacrolimus or rapamycin 3 months after kidney transplantation: a prospective, protocol biopsy-guided study. Transplant Proc. 2011 Mar;43(2):519-23.

Patel S, Pankewycz O, Kohli R, Said M, Alnimri M, Feng L, Laftavi MR. Obesity in renal transplantation: the role of induction therapy on long-term outcomes. Transplant Proc. 2011 Mar; 43(2):469-71.

Muna A. Al- Nimri, Radko Komers, Terry T. Oyama, Arohan R. Subramanya, Jessie N. Lindsley, and Sharon Anderson. Endothelial derived vasoactive mediators in polycystic kidney disease. Kidney International 2003 63(5): 1776-1784

UCDAVIS HEALTH

Muna Alnimri, M.B.B.S.

Muna Al Nimri, Maan Hadidi. Acute renal failure after cardiac catheterization and coronary artery bypass graft in an elderly patient. Saudi Journal of Kidney Diseases and Transplantation 2002 13 (1): 55-59

Thomas M. Kennefick, Muna A. Al-Nimri, Terry T. Oyama, Michelle M. Thompson, Francis J. Kelly, Justin G. Chapman, and Sharon Anderson. Hypertension and renal injury in experimental polycystic kidney disease. Kidney International 1999 56(6): 2181-2190

UCDAVIS HEALTH